Patents by Inventor Te-Jung Chen

Te-Jung Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Radioactive arsenic-containing compounds and their uses in the treatment of tumors
    Patent number: 7803350
    Abstract: This invention provides a process for producing a radioactive arsenic-containing compound, comprising the steps of: (i) subjecting an arsenic-containing compound to a neutron irradiation treatment, said arsenic-containing compound being selected from a group consisting of As2O3, As2S3, As2S2, and a combination thereof, such that the arsenic element contained in the arsenic-containing compound is converted to a radioactive arsenic isotope; and (ii) recovering the resultant product from step (i). This invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the radioactive arsenic-containing compound and a pharmaceutically acceptable carrier. The pharmaceutical composition can be used in the treatment of tumors/cancers such as hematological malignancies and solid tumors.
    Type: Grant
    Filed: July 30, 2007
    Date of Patent: September 28, 2010
    Assignees: Institute of Nuclear Energy Research Rocaec, TTY Biopharm Company, Limited
    Inventors: Te-Wei Lee, Chun-Ying Huang, Ming-Shiuan Wu, Te-Jung Chen, Kwo-Ping Chang, Shiang-Rong Chang, Shyh-Yi Chyi, Chih-Hsien Chang, Yin-Mao Hsu, Kuo-Hsien Fan, Wei-Chuan Hsu, Ying-Kai Fu, Charng-Feng Kao
  • Radioactive arsenic-containing compounds and their uses in the treatment of tumors
    Publication number: 20080003177
    Abstract: This invention provides a process for producing a radioactive arsenic-containing compound, comprising the steps of: (i) subjecting an arsenic-containing compound to a neutron irradiation treatment, said arsenic-containing compound being selected from a group consisting of As2O3, As2S3, As2S2, and a combination thereof, such that the arsenic element contained in the arsenic-containing compound is converted to a radioactive arsenic isotope; and (ii) recovering the resultant product from step (i). This invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the radioactive arsenic-containing compound and a pharmaceutically acceptable carrier. The pharmaceutical composition can be used in the treatment of tumors/cancers such as hematological malignancies and solid tumors.
    Type: Application
    Filed: July 30, 2007
    Publication date: January 3, 2008
    Applicants: TTY Biopharm Company, Limited, Institute of Nuclear Energy Research Rocaec
    Inventors: Chun-Ying Huang, Ming-Shiuan Wu, Te-Wei Lee, Te-Jung Chen, Kwo-Ping Chang, Shyh-Yi Chyi, Yin-Mao Hsu, Kuo-Hsien Fan, Wei-Chuan Hsu, Ying-Kai Fu, Charng-Feng Kao, Shiang-Rong Chang, Chih-Hsien Chang
  • Use and manufacturing process for liposomal doxorubicin pharmaceutical composition
    Publication number: 20050129752
    Abstract: The present invention provides a method of treating mammals having pancreatic cancer by administering a liposomal doxorubicin pharmaceutical composition, and a process of manufacturing the composition.
    Type: Application
    Filed: October 1, 2004
    Publication date: June 16, 2005
    Inventors: Te-Jung Chen, Sze-Yuan Yang, Chia-Ning Liu, Chun-Ying Huang, Jung-Chin Lin
  • Radioactive arsenic-containing compounds and their uses in the treatment of tumors
    Publication number: 20040213737
    Abstract: This invention provides a process for producing a radioactive arsenic-containing compound, comprising the steps of: (i) subjecting an arsenic-containing compound to a neutron irradiation treatment, said arsenic-containing compound being selected from a group consisting of As2O3, As2S3, AS2S2, and a combination thereof, such that the arsenic element contained in the arsenic-containing compound is converted to a radioactive arsenic isotope; and (ii) recovering the resultant product from step (i).
    Type: Application
    Filed: March 3, 2004
    Publication date: October 28, 2004
    Applicants: TTY BIOPHARM COMPANY, LIMITED, INSTITUTE OF NUCLEAR ENERGY RESEARCH ROCAEC
    Inventors: Chun-Ying Huang, Ming-Shiuan Wu, Te-Wei Lee, Te-Jung Chen, Kwo-Ping Chang, Shyh-Yi Chyi, Yin-Mao Hsu, Kuo-Hsien Fan, Wei-Chuan Hsu, Ying-Kai Fu, Charng-Feng Kao, Shiang-Rong Chang, Chih-Hsien Chang